<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">increased rate of secondary bacterial or fungal infection (RR 2·0, 95% CI 1·0–3·8; 
 <italic>p</italic> = .04), and longer stay in an intensive care unit (mean difference 2.1, 95% CI 1.2–3.1; 
 <italic>p</italic> &lt; .0001) in patients receiving CS [
 <xref rid="bb0235" ref-type="bibr">47</xref>]. Moreover, a review exploring treatments for ARDS, including six studies with a total of 574 patients, concluded that insufficient evidence exists to recommend CS treatment [
 <xref rid="bb0240" ref-type="bibr">48</xref>]. Overall, no clear reason exists to expect that patients with COVID-19 infection will benefit from CS, and they might be more likely to be harmed with such therapy [
 <xref rid="bb0245" ref-type="bibr">49</xref>]. In fact, current interim guidance from WHO on clinical management of COVID-19 infection advises against the use of CS unless indicated for another reason [
 <xref rid="bb0050" ref-type="bibr">10</xref>].
</p>
